Argenx Se · EURONEXT:ARGX
Argenx — Corporate Update (June 2023)
15 slides from Argenx's corporate update, Jun 21, 2023
Slide 1: VYVGART Hytrulo FDA Approval Call
VYVGART ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) FDA Approval Call June 21, 2023
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter
Slide 3: VYVGART for Generalized Myasthenia Gravis
VYVGART for Generalized Myasthenia Gravis VYVGART and VYVGART Hytrulo are indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive NOW TWO FDA-APPROVED PRODUCTS 3
Slide 4: Generalized Myasthenia Gravis Patient Experience
GENERALIZED MYASTHENIA GRAVIS PATIENT EXPERIENCE gMG is characterized by debilitating muscle weakness and fatigue. Despite taking an average of 2.3 current treatments, 61% of patients have poor well-being according to WHO-5 Index 1/2 of Patients have been diagnosed with depression or anxiety in addi
Slide 5: Redefining What 'Well-Controlled' Means for the Patient
Redefining What ‘Well-Controlled’ Means for the Patient 5 Achieve minimal symptom expression Reduce reliance on broad immunosuppressants Regain control of their lives, including professionally and socially Minimize treatment burden We want to transform gMG treatment for patients
Slide 6: Consistent Responses Across IV and SC: ADAPT-SC Bridging Study
EXPLORATORY MSE: MG-ADL score of 0 or 1 n=20/54 n=21/55 VYVGART Hytrulo VYVGART Innovative Phase 3 Bridging Study Consistent Responses Across IV and SC MG-ADL, Myasthenia Gravis Activities of Daily Living; QMG, Quantitative Myasthenia Gravis; MSE, minimal symptom expression Howard JF, et al. Lancet
Slide 7: Adverse Reactions, Indication and Dosing
ADVERSE REACTIONS • The most common adverse reactions ( ≥10%) in patients treated with intravenous VYVGART were respiratory tract infections, headaches, and urinary tract infection. Additional common adverse reactions with VYVGART Hytrulo are injection site reactions. VYVGART® Hytrulo (efgartigimod
Slide 8: Best-in-Class Patient Support and Simplicity of Access
8 Best-in-Class Patient Support Simplicity of Access Flexibility and Choice for Patients Chronic autoimmune diseases are complicated VYVGART makes treatment simple Broad HCP Use and Adoption
Slide 9: VYVGART Simplifies Treatment of gMG in the Community
VYVGART Simplifies Treatment of gMG in the Community ~17,000 Lowering the bar for treatment initiation and expanding access for the current gMG patients we can address with VYVGART Demonstrated Efficacy: 78% responders across first two treatment cycles in ADAPT Simple Treatment Initiation: broad acc
Slide 10: Simplicity of Access: Driving Choice By Value to the Patient
Simplicity of Access: Driving Choice By Value to the Patient Creating a new standard for gMG treatment Flexibility and choice for patients IV has broad and early access Annual net price to be similar across IV and SC treatment options ESTABLISHED VALUE TO PATIENTS PARITY PRICING PRODUCT CHOICE BY MA
Slide 11: My VYVGART Path Access Support and Education
My VYVGART Path is Available to Provide Access Support and Education 11 PERSONALIZED SUPPORT Educate on VYVGART and VYVGART Hytrulo Treatment Resources and Information Navigate Insurance Process Financial Assistance Available
Slide 12: Reaching gMG Patients Across the Globe
Reaching gMG Patients Across the Globe VYVGART Approved December 2021 VYVGART Hytrulo Approved June 2023 Japan Approved January 2022 Europe Approved September 2022 China (Zai Lab) Expected approval in 2023 Canada Expected approval in 2023 United Kingdom Approved March 2023 Israel (Medison) Approved
Slide 13: gMG Is Just the Beginning
gMG is just the beginning 13 PC-POTS >500K ANCA 105K TED 100K Sjogren’s 330K Membranous Nephropathy 80K BP 52K gMG 65K ITP 57K Myositis 63K Pemphigus 19K CIDP 16K Lupus Nephritis 40K AMR 8K Patient numbers are U.S. prevalence from argenx market research clinical indications with successful proof-of-
Slide 14: Empasiprubart for Multifocal Motor Neuropathy: ARDA Study
A phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of two dose regimens of empasiprubart (ARGX-117) in adults with multifocal motor neuropathy Empasipruba
Slide 15: Our Mission Continues
Our mission continues… Humility Innovation Excellence Co-Creation Empowerment 15